Patient Guide: A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 11 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT07081646
Status: 🟢 Enrolling Now
Condition: Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 11 locations across the country.

Top locations include:
  • • Phoenix, Arizona
  • • San Francisco, California
  • • Detroit, Michigan
  • • And 8 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. - Join Clinical Trial NCTNCT07081646

How to Join This Clinical Trial - NCTNCT07081646

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT07081646 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 11 locations. Find a study site near you:

Clinical Research Site

Phoenix, Arizona 85028 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

San Francisco, California 94143 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Detroit, Michigan 48201 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Rochester, Minnesota 55905 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

St Louis, Missouri 63110 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

New York, New York 10032 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10065 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Cleveland, Ohio 44195 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Nashville, Tennessee 37232 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Calgary, Alberta T2N 5G2 - Canada

Status: NOT_YET_RECRUITING

And 1 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships